OpenEvidence hits $12B valuation with $250M raise after 18M AI‑assisted consultations
AI health startup OpenEvidence, which describes its clinical decision support platform as a digital “brain extender” for physicians, has secured a massive $250 million funding round, pushing its valuation to around $12 billion. The raise follows rapid adoption of its tool across hospitals and clinics, where it has already been used in an estimated 18 million medical consultations.
The deal underscores investor conviction that AI in healthcare is moving beyond experimental pilots into core clinical workflows. It also signals intensifying competition in the race to build trusted, regulatory‑compliant clinical decision support systems that can safely sit alongside doctors in exam rooms and hospitals.
What OpenEvidence’s ‘brain extender’ actually does
OpenEvidence positions its platform as a way to augment, not replace, clinicians. The company’s software ingests a wide range of medical information — including peer‑reviewed research, clinical guidelines, drug databases and, where permitted, anonymised patient data — and surfaces evidence‑based insights for doctors in real time.
From symptom to suggested pathway
When a physician enters symptoms, lab results or a draft diagnosis, the OpenEvidence engine uses advanced AI algorithms and natural language processing to:
- Highlight likely differential diagnoses based on current evidence
- Flag potential drug interactions and contraindications
- Surface up‑to‑date treatment guidelines and dosing recommendations
- Provide citations to the underlying clinical studies and guideline sources
The company refers to this as a “brain extender” because it aims to expand a doctor’s accessible knowledge base at the point of care, especially in complex or rare cases where no individual can reasonably memorise all relevant data.
Designed to fit into existing workflows
Crucially, the platform is built to integrate with existing electronic health record (EHR) systems and hospital software, rather than requiring clinicians to adopt a standalone interface. That integration is key to adoption, allowing OpenEvidence prompts and summaries to appear directly within the tools doctors already use for charting and ordering tests.
The company says this approach has helped drive use across multiple specialties, from primary care and internal medicine to oncology and cardiology, contributing to its tally of more than 18 million AI‑supported consultations to date.
Why investors are betting big on AI decision support
The $250 million funding round places OpenEvidence among the most highly valued private companies in the digital health and medical AI sectors. While the company has not publicly disclosed all investors, the size and valuation signal strong interest from late‑stage growth funds that traditionally back firms on the cusp of large‑scale commercial expansion.
Healthcare’s productivity and safety problem
Health systems globally are grappling with rising demand, clinician burnout and mounting complexity in diagnostics and treatment. New drugs, devices and protocols are being introduced at a pace that makes it increasingly difficult for even highly specialised clinicians to stay fully current.
Investors see platforms like OpenEvidence as a way to address several structural challenges:
- Reducing diagnostic error by ensuring access to the latest evidence
- Supporting overworked clinicians with rapid, structured summaries
- Standardising care around best‑practice clinical guidelines
- Shortening the lag between new research and bedside application
By positioning itself as a safety‑oriented “co‑pilot” rather than an autonomous decision‑maker, OpenEvidence is pitching a model that regulators and hospital leaders may find more acceptable than fully automated diagnosis engines.
Regulation, safety and the ‘doctor in the loop’ model
As with any AI in medicine, the core questions for OpenEvidence are reliability, transparency and accountability. The company emphasises that its system is built around a strict “doctor in the loop” philosophy: the software offers evidence‑based suggestions, but the final clinical judgement remains with the human professional.
Evidence sourcing and auditability
OpenEvidence says its platform is designed to be auditable. For every recommendation or risk flag, the system can display linked citations, including the title of the study, journal, publication date and key findings. This is intended to help clinicians quickly verify whether a suggestion is grounded in high‑quality evidence or emerging, lower‑confidence data.
Such transparency is increasingly important as regulators in the US, Europe and other regions refine frameworks for software as a medical device (SaMD) and AI‑based clinical tools. Hospitals are under pressure to ensure that any AI incorporated into care pathways can be scrutinised and monitored for bias, safety and performance drift.
Data privacy and security expectations
Handling sensitive health data also forces platforms like OpenEvidence to operate under strict data protection regimes, including HIPAA in the United States and GDPR in Europe. The company says its deployments use encryption, access controls and, where possible, de‑identification or pseudonymisation of patient records. Hospitals typically insist on detailed audit logs and controls over how data is used to further train or refine AI models.
Competitive landscape and strategic direction
The fresh capital gives OpenEvidence significant firepower in a crowded market that includes both established health IT vendors and newer AI‑native entrants. Large technology and cloud providers are also pushing hard into clinical AI, bundling decision support into their broader healthcare offerings.
Expansion plans and product roadmap
With a $12 billion valuation, the company is widely expected to accelerate:
- Geographic expansion into new markets in Europe, North America and Asia
- Deeper integration with major EHR platforms and hospital systems
- Specialty‑specific modules, for example in oncology, cardiology and pediatrics
- New tools for medical education and resident training
Industry observers also expect OpenEvidence to invest heavily in real‑world evidence generation — using aggregated, anonymised data from its deployments to study outcomes and demonstrate whether its recommendations actually improve safety, cost and patient health at scale.
What 18M consultations reveal about AI’s role in clinics
The milestone of 18 million AI‑supported consultations provides a glimpse into how quickly AI‑enabled decision support is becoming embedded in everyday care. For now, tools like OpenEvidence are being used as an additional lens on complex cases, a double‑check on medication choices, and a rapid way to surface guidelines without leaving the EHR screen.
As health systems measure the impact of these tools on clinical outcomes, workflow efficiency and patient safety, their findings will likely shape how regulators, payers and professional bodies view the next generation of AI in medicine. With fresh capital, a double‑digit billion valuation and millions of real‑world consultations already on record, OpenEvidence is positioning itself at the centre of that emerging debate.